SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 8)
Under the Securities Exchange Act of 1934*
PDL BioPharma, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
69329Y104
- --------------------------------------------------------------------------------
(CUSIP Number of Class of Securities)
Daniel S. Loeb
Third Point LLC
390 Park Avenue
New York, NY 10022
(212) 224-7400
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copies to:
Michael A. Schwartz, Esq.
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, NY 10019-6099
(212) 728-8000
October 15, 2007
- --------------------------------------------------------------------------------
(Date of Event which Requires
Filing of this Schedule)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of ss.ss. 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the
following box: [ ]
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 240.13d-7 for other
parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
- ---------------------------------- ----------------------
CUSIP No. 69329Y104 Page 2 of 12 Pages
- ---------------------------------- ----------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Third Point LLC
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
8 SHARED VOTING POWER
NUMBER OF SHARES
BENEFICIALLY OWNED 6,000,000
BY EACH REPORTING --------- ------------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
6,000,000
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
6,000,000
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.1%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
OO
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- ---------------------------------- ----------------------
CUSIP No. 69329Y104 Page 3 of 12 Pages
- ---------------------------------- ----------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Third Point Offshore Fund, Ltd.
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
8 SHARED VOTING POWER
NUMBER OF SHARES
BENEFICIALLY OWNED 3,998,000
BY EACH REPORTING --------- ------------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
3,998,000
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
3,998,000
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.4%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
OO
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- ---------------------------------- ----------------------
CUSIP No. 69329Y104 Page 4 of 12 Pages
- ---------------------------------- ----------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Daniel S. Loeb
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
8 SHARED VOTING POWER
NUMBER OF SHARES
BENEFICIALLY OWNED 6,000,000
BY EACH REPORTING --------- ------------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
6,000,000
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
6,000,000
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.1%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ----------- --------------------------------------------------------------------
SCHEDULE 13D
- ---------------------------------- ----------------------
CUSIP No. 69329Y104 Page 5 of 12 Pages
- ---------------------------------- ----------------------
- ----------- --------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Jason Aryeh
- ----------- --------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [ ]
(b) [X]
- ----------- --------------------------------------------------------------------
3 SEC USE ONLY
- ----------- --------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- ----------- --------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e) [ ]
- ----------- --------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- --------------------- --------- ------------------------------------------------
7 SOLE VOTING POWER
0
--------- ------------------------------------------------
8 SHARED VOTING POWER
NUMBER OF SHARES
BENEFICIALLY OWNED 0
BY EACH REPORTING --------- ------------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
--------- ------------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- ----------- --------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
0
- ----------- --------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
- ----------- --------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
- ----------- --------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
IN
- ----------- --------------------------------------------------------------------
This Amendment No. 8 to Schedule 13D ("Amendment No. 8") amends the
Schedule 13D filed on March 5, 2007 (as amended by Amendment No. 1 thereto filed
on March 21, 2007, Amendment No. 2 thereto filed on April 11, 2007, Amendment
No. 3 thereto filed on April 18, 2007, Amendment No. 4 thereto filed on May 22,
2007, Amendment No. 5 thereto filed on May 31, 2007, Amendment No. 6 thereto
filed on July 17, 2007, Amendment No. 7 thereto filed on August 30, 2007 and
this Amendment No. 8, the "Schedule 13D") and is being filed on behalf of Third
Point LLC, a Delaware limited liability company (the "Management Company" or
"Third Point"), Third Point Offshore Fund, Ltd., a Cayman Islands limited
liability exempted company (the "Offshore Fund"), Daniel S. Loeb, an individual
("Mr. Loeb", and together with the Management Company and the Offshore Fund, the
"Third Point Reporting Persons"), and Jason Aryeh, an individual ("Mr. Aryeh",
and together with the Third Point Reporting Persons, the "Reporting Persons").
This Amendment No. 8 relates to the common stock, par value $0.01 per share (the
"Common Stock"), of PDL BioPharma, Inc., a Delaware corporation (the "Company").
The Management Company is the investment manager or adviser to a variety of
hedge funds and managed accounts (such funds and accounts, including the
Offshore Fund, the "Funds"). The Funds directly own the Common Stock to which
this Schedule 13D relates, and Mr. Loeb and the Management Company may be deemed
to have beneficial ownership over such Common Stock by virtue of the authority
granted to them by the Funds to vote and to dispose of the securities held by
the Funds, including the Common Stock. Mr. Aryeh may be deemed to have
beneficial ownership of the shares of Common Stock directly owned by JALAA
Equities, LP ("JALAA") by virtue of his ability to vote and/or to dispose of the
securities held by JALAA, including the Common Stock.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is hereby amended and restated as follows:
The Funds have expended an aggregate of approximately $107,371,520 of their
own investment capital to acquire the 6,000,000 shares of Common Stock held by
them. The Offshore Fund has expended an aggregate of approximately $73,410,220
of its own investment capital to acquire its 3,998,000 shares of Common Stock.
Item 4. Purpose of Transaction.
Item 4 of the Schedule 13D is hereby amended by adding the following
thereto:
On October 17, 2007, Third Point sent a letter to the members of the
Company's Board of Directors in which it acknowledged positive developments
relating to the Company's announced intentions to commence a sale process but
expressed concern that the Board does not include a Third Point representative
and that the Company is being led by L. Patrick Gage as Interim Chief Executive
Officer. In the letter, Third Point reiterated its belief that the shares remain
undervalued and stated that, as one of the Company's largest shareholders, it
will be carefully tracking developments at the Company and assessing its
options.
A copy of the letter is attached to this Amendment No. 8 as an exhibit and
incorporated herein by reference in its entirety.
6
Item 5. Interest in Securities of the Issuer.
Items 5(a), 5(b) and 5(c) of the Schedule 13D are hereby amended and
restated as follows:
(a) As of the date hereof, the Management Company and Mr. Loeb beneficially
own 6,000,000 shares of Common Stock (the "Third Point Shares"). The Third Point
Shares represent 5.1% of the 116,831,008 shares of Common Stock outstanding as
of August 2, 2007, as reported in the Company's Quarterly Report on Form 10-Q
for the quarterly period ended June 30, 2007. The percentages used herein and in
the rest of this statement are calculated based upon this number of outstanding
shares. As of the date hereof, the Offshore Fund directly beneficially owns
3,998,000 shares of Common Stock, representing 3.4% of the outstanding shares of
Common Stock. As of the date hereof, none of the individual Funds own a number
of shares of Common Stock representing more than 5% of such total. Mr. Aryeh no
longer beneficially owns any shares of Common Stock as of the date hereof.
(b) The Management Company and Mr. Loeb share voting and dispositive power
over the 6,000,000 shares of Common Stock held by the Funds. The Management
Company, Mr. Loeb and the Offshore Fund share voting power and dispositive power
over the 3,998,000 shares of Common Stock held by the Offshore Fund.
(c) Schedule A hereto sets forth certain information with respect to
transactions by the Funds (at the direction of the Management Company and Mr.
Loeb) in the Common Stock since the most recent filing on Schedule 13D. Schedule
B hereto sets forth certain information with respect to transactions by the
Offshore Fund (at the direction of the Management Company and Mr. Loeb) in the
Common Stock since the most recent filing on Schedule 13D. Schedule C sets forth
certain information with respect to transactions by Mr. Aryeh in the Common
Stock since the most recent filing on Schedule 13D.
All of the transactions set forth on Schedules A, B and C were effected in
open market transactions in the NASDAQ Global Select Market. Except as set forth
on Schedules A, B and C since the most recent filing on Schedule 13D there were
no transactions in the Common Stock effected by any of the Management Company,
Mr. Loeb, the Offshore Fund or Mr. Aryeh, nor, in the case of the Management
Company and the Offshore Fund and to the best of their knowledge, any of their
directors, executive officers, general partners or members.
(d) Other than the Funds which directly hold the Third Point Shares, and
except as set forth in this Item 5, no person is known to have the right to
receive or the power to direct the receipt of dividends from, or the proceeds
from the sale of, the Third Point Shares.
(e) The Offshore Fund ceased to be the beneficial owner of more than five
percent of the outstanding Common Stock on October 16, 2007.
7
Item 7. Material to be Filed as Exhibits.
99.1. Letter, dated October 17, 2007, from Third Point to Karen A. Dawes,
Bradford S. Goodwin, Joseph Klein III, Laurence Jay Korn, Ph.D.,
Richard Murray, Ph.D., John S. Saxe, Esq., L. Patrick Gage, Ph.D.,
the members of the Board of Directors of the Company.
[Signatures on following page]
8
SIGNATURES
After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.
Dated: October 17, 2007
THIRD POINT LLC
By: Daniel S. Loeb, Chief Executive Officer
By: /s/ Justin Nadler
-----------------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
THIRD POINT OFFSHORE FUND, LTD.
By: Daniel S. Loeb, Director
By: /s/ Justin Nadler
-----------------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
DANIEL S. LOEB
By: /s/ Justin Nadler
-----------------------------------------
Name: Justin Nadler
Title: Attorney-in-Fact
/s/ Jason Aryeh
-----------------------------------------------
Jason Aryeh
[SIGNATURE PAGE TO AMENDMENT NO. 8 TO SCHEDULE 13D
WITH RESPECT TO PDL BIOPHARMA, INC.]
Schedule A
----------
(Transactions by the Funds in Common Stock
since the most recent filing on Schedule 13D)
Date Transaction Shares Price Per Share($)
---- ----------- ------ ------------------
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
08/31/07 BUY 54,100 19.51
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
08/31/07 (54,100) 19.51
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
BUY
09/28/07 68,000 21.61
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
09/28/07 (68,000) 21.61
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/02/07 (350,000) 22.76
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/02/07 (750,000) 22.73
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/04/07 (60,000) 23.50
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (30,000) 22.78
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (200,000) 22.65
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (100,000) 22.30
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (69,500) 21.90
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (620,000) 21.84
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/16/07 (1,355,500) 21.81
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/16/07 (1,350,000) 21.80
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/17/07 (410,000) 21.62
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/17/07 (5,000) 21.59
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
Schedule B
----------
(Transactions by the Offshore Fund in Common Stock
since the most recent filing on Schedule 13D)
Date Transaction Shares Price Per Share($)
---- ----------- ------ ------------------
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
08/31/07 SELL (11,700) 19.51
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
09/28/07 (62,000) 21.61
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/02/07 (234,900) 22.76
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/02/07 (499,300) 22.73
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/04/07 (38,000) 23.50
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (150,000) 22.65
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (66,700) 22.30
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (46,200) 21.90
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/15/07 (413,100) 21.84
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/16/07 (901,300) 21.81
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/16/07 (899,800) 21.80
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/17/07 (273,900) 21.62
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
SELL
10/17/07 (3,300) 21.59
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
Schedule C
----------
(Transactions by Mr. Aryeh in Common Stock
since the most recent filing on Schedule 13D)
Date Transaction Shares Price Per Share($)
---- ----------- ------ ------------------
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
10/16/07 SELL 1,011 21.79
- ------------------------ ---------------------------- --------------------------------- -----------------------------------
Exhibit 99.1
[Third Point Letterhead]
October 17, 2007
Ms. Karen A. Dawes
Mr. Bradford S. Goodwin
Mr. Joseph Klein III
Laurence Jay Korn, Ph.D.
Richard Murray, Ph.D.
John S. Saxe, Esq.
L. Patrick Gage, Ph.D.
PDL BioPharma, Inc.
34801 Campus Drive
Fremont, CA 94555
PDL Board Members:
We are encouraged by PDL's October 1st press release announcing that the Board
will actively seek the sale of the entire Company or all of its component
pieces. We are also pleased with the progress apparently being made by the
Merrill Lynch investment bankers in spearheading this process and advancing it
expeditiously to a successful conclusion.
Despite these positive developments, we are disappointed that the sale process
is still being led by a Board that does not include a Third Point
representative, and that Patrick Gage remains the Company's CEO, despite having
demonstrated his unsuitability. Accordingly, although we remain convinced that
PDLI shares are undervalued, and that a sale will maximize shareholder value, in
light of your continuing refusal to provide us with a voice in the Company's
affairs through a Board seat, we have reduced our position.
Despite the reduction in our PDLI position, we have maintained a holding above
the 13D filing threshold, and remain one of the Company's largest shareholders.
We will be carefully watching developments, and assessing our options, as events
unfold.
Sincerely,
/s/ Daniel S. Loeb
Daniel S. Loeb